Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels - Université de La Réunion
Article Dans Une Revue Immunologic Research Année : 2022

Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels

Résumé

No abstract available

Domaines

Immunologie

Réunion Univ  : Connectez-vous pour contacter le contributeur

https://hal.univ-reunion.fr/hal-04104444

Soumis le : mercredi 24 mai 2023-09:40:32

Dernière modification le : lundi 1 juillet 2024-09:29:33

Consulter le texte intégral

Dates et versions

hal-04104444 , version 1 (24-05-2023)

Identifiants

Citer

Anthony Dobi, Arthur Dubernet, Mahary Lalarizo Rakoto, Anne-Laure Sandenon Seteyen, Damien Vagner, et al.. Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels. Immunologic Research, 2022, 70 (5), pp.714-719. ⟨10.1007/s12026-022-09269-w⟩. ⟨hal-04104444⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INSERM AFRIQ CNRS UNIV-REUNION PIMIT UR-EPI
37 Consultations
0 Téléchargements

Altmetric

Partager

More